UNASSIGNED: @entity6 ( @entity6 ) accounts for more than 90% of all cases of @entity6 ( @entity6 ). Diabetic @entity9 (DNP) is a common complication of @entity6 . @entity39939 is a natural bioactive component extracted from the Sinomenium acutum and has anti-inflammatory effects. The aim of our study was to investigate the effects of @entity39939 on DNP mediated by the P2X3 receptor in dorsal root ganglia (DRG). The @entity3347 ( @entity3347 ) and thermal withdrawal latency (TWL) in @entity6 rats were lower than those of control rats. @entity3347 and TWL in @entity6 rats treated with @entity39939 were higher compared with those in @entity6 rats. The expression levels of the P2X3 protein and mRNA in @entity6 rat DRG were higher compared with those of the control, while those in @entity6 rats treated with @entity39939 were significantly lower compared with those of the @entity6 rats. @entity39939 significantly inhibited P2X3 agonist @entity855 -activated currents in HEK293 cells transfected with the P2X3 receptor. @entity39939 decreased the phosphorylation and activation of P38MAPK in @entity6 DRG. Therefore, @entity39939 treatment may suppress the up-regulated expression and activation of the P2X3 receptor and relieve the @entity1931 potentiated by the activation of P38MAPK in @entity6 rats.

The effect of @entity39939 in XXXX mediated by the P2X3 receptor in dorsal root ganglia.

@entity3347 :: ('MESH:D013375', 'Disease') :: ['MWT', 'mechanical withdrawal threshold'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus', 'DM', 'T2DM', 'Type 2 diabetes mellitus'] @entity39939 :: ('MESH:C009271', 'Chemical') :: ['Sinomenine', 'sinomenine'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP']
@entity9 :: (MESH:D009437,Disease) :: ['diabetic neuropathic pain']
